Publications

Tocagen’s research and technology has been included in numerous peer-reviewed scientific journals and presented at scientific and medical meetings. Browse the articles and presentations below to learn more.

Immune profile of tumor microenvironment helps predict response in patients treated with an investigational immunotherapeutic consisting of a retroviral replicating vector (Toca 511) and an extended-release formulation of 5-fluorocytosine (Toca FC)
Presentation by Derek Ostertag, Ph.D., senior director of R&D Diagnostics at Tocagen.
Review the poster.

A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Followed by Toca FC in Patients With Advanced Cancer
AACR 2018 poster presentation by Jaime Merchan, M.D., director, Phase 1 clinical trials program at Sylvester Comprehensive Cancer Center, part of UHealth, the University of Miami Health System; associate professor of medicine at the University of Miami Miller School of Medicine.
Review the poster.

Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics
SNO-SCIDOT oral presentation by Timothy Cloughesy, M.D., director of the University of California, Los Angeles, Neuro-Oncology Program.
Review the presentation.

Intravenous Delivery of Toca 511 in Patients With High Grade Glioma Results in Quantifiable Expression of Cytosine Deaminase in Tumor Tissue
SNO-SCIDOT poster presentation by Tiffany Montellano, Ph.D., medical science liaison at Tocagen.
Review the poster.

Intravenous delivery of Toca 511 in patients with high grade glioma results in quantifiable expression of cytosine deaminase in tumor tissue
SNO oral presentation by Tobias Walbert, M.D., Ph.D., co-director of the Hermelin Brain Tumor Center at Henry Ford Hospital.
Review the presentation.

Durable Responses Observed in IDH1 Wildtype and Mutant Recurrent High Grade Glioma with Toca 511 & Toca FC Treatment
SNO oral presentation by Timothy Cloughesy, M.D., director of the University of California, Los Angeles, Neuro-Oncology Program.
Review the presentation.

Toca 511 and 5-FC induces T cell-mediated antitumor immunity in a mouse glioma model which is enhanced by the addition of a therapeutic antibody against CTLA-4 and correlative with a reduction in memory T regulatory cells.
SNO poster presentation by Douglas Jolly, Ph.D., executive vice president of research and pharmaceutical development at Tocagen.
Review the poster.

Immunological activation in responding patients with recurrent HGG after treatment with Toca 511 & Toca FC: Results from a phase 1 trial
SNO e-talk by Derek Ostertag, Ph.D., director, R&D diagnostics at Tocagen.
Review the presentation.

T cell priming by Toca 511 and 5-FC coupled with T regulatory cell depletion by αCTLA-4 synergistically enhances anti-tumor immune memory in a mouse model of glioma
SITC poster presentation by Leah Mitchell, Ph.D., associate director, translational research at Tocagen.
Review the poster.

Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment
AACR-NCI-EORTC oral presentation by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and head of the University of Minnesota Medical School Department of Neurosurgery
Review the presentation.
Watch the webcast.

Long-term follow-up data from 126 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trial.
ASGCT podium presentation by Douglas Jolly, Ph.D., executive vice president of research and pharmaceutical development at Tocagen.
Review the presentation.

TOCA 511 & 5-FC: Anti-tumor activity, immune memory and prolonged survival even at low infection levels.
ASGCT poster presentation by Kader Yagiz, Ph.D., research scientist at Tocagen.
Review the poster.

Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model
Neuro-Oncol.
Published online: April 6, 2017
Leah A. Mitchell, et al.
Read the article.

Retroviral replicating vector–mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity
Neuro-Oncol.
Published online: April 6, 2017
Kei Hiraoka, et al.
Read the article.

Retroviral replicating vector delivery of miR-PDL1 inhibits immune checkpoint PDL1 and enhances immune responses in vitro
Mol. Ther. — Nucleic Acids.
Published online: Feb. 8, 2017
Amy H. Lin, et al.
Read the article.

Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
Sci. Transl. Med.
2016; 8(341): 341ra75.
Timothy F. Cloughesy, et al.
Read the abstract.

MethylMeter: bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples.
Epigenomics.
2016;8(6):747-765.
David McCarthy, …Oscar Diago, et al.
Read the article.

Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Neuro-Oncol.
2016;18(10):1390-1401.
Kader Yagiz, et al.
Read the abstract.

A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models
Molecular Therapy Oncolytics
Published online: December 29, 2017
Kader Yagiz, et al.
Read the abstract.

Efficient Therapeutic Protein Expression Using Retroviral Replicating Vector with 2A Peptide in Cancer Models.
Hum. Gene Ther.
2017; [epub ahead of print].
Hofacre A. et al.
Read the abstract.

Extensive Replication of a Retroviral Replicating Vector Can Expand the A Bulge in the Encephalomyocarditis Virus Internal Ribosome Entry Site and Change Translation Efficiency of the Downstream Transgene.
Hum. Gene Ther. Methods
2016;27(2):59-70.
Lin AH. et al.
Read the abstract.

Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.
Hum. Gene. Ther. Methods
2016;27(1):17-31.
Twitty CG. et al.
Read the abstract.

Intravenous administration of a retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in an orthotopic immune-competent mouse glioma model.
Hum. Gene Ther.
2015;26(2): 82-93.
Huang T. et al.
Read the abstract.

Blockade of Type I Interferon (IFN) Production by Retroviral Replicating Vectors and Reduced Tumor Cell Responses to IFN Likely Contribute To Tumor Selectivity.
J Virol.
2014; 88(17): 10066-10077.
Lin AH. et al.
Read the abstract.

Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.
Cancer Gene Ther.
2014; 21(10): 405-410.
Takahashi M. et al.
Read the abstract.

MicroRNA 142-3p Attenuates Spread of Replicating Retroviral Vector in Hematopoietic Lineage-Derived Cells While Maintaining an Antiviral Immune Response.
Hum. Gene Ther.
2014;25(8):759-771.
Lin AH. et al.
Read the abstract.

Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids.
Mol. Ther. — Methods & Clinical Development.
2014; 1, 14024.
Burnett R. et al.
Read the article.

Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Cancer Gene Ther.
2013; 20(10): 544-551.
Huang TT. et al.
Read the abstract.

Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model.
Cancer Gene Therapy.
2013; 20(6): 336–334.
Dali Yin,….Harry E. Gruber, et al.
Read the article.

Not Reinventing the Wheel: Applying the 3Rs Concepts to Viral Vector Gene Therapy Biodistribution Studies.
Human Gene Ther. Clin. Dev.
2013; 24: 1–4.
Timothy K. MacLachlan,…DJ. Jolly, et al.
Read the article.

Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression.
Mol. Ther.
2012; 20(9): 1689-1698.
Perez O. and Logg C. et al.
Read the article.

(2012) Chapter 11: Retroviral Replicating Vectors in Cancer, in Friedmann T.
(ed) Gene Transfer Vectors for Clinical Application, Academic Press, 199-228.
Logg, C. R. et al.
Read the abstract.

Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Neurooncol.
2012; 14(2): 145-159.
Ostertag D. et al.
Read the article. Read the supplementary data.

We’re hiring.

Tocagen is looking for the best and the brightest to join our team. Can you help further our goal to fight cancer? We offer competitive benefits and an invigorating work environment.